



15 February 2016

The Companies Office
Australian Securities Exchange Limited
Sydney

Dr. Peter French appointed Executive Director of Bioxyne Limited

Bioxyne Limited (the Company) is pleased to announce the appointment of Dr Peter French as an Executive Director of the Company.

The appointment of Dr French is a key strategic milestone in the implementation of the Company's business plan to extend the distribution of the Company's *Lactobacillus fermentum* PCC strain of probiotics.

The aim is to widen the Company's distribution channels, and to increase sales through the introduction of a range of complementary over-the-counter dietary wellness supplements. As part of this aim, the Company will invest in producing further scientific and clinical evidence of the effectiveness of PCC to promote health and wellness. Dr French will lead this effort.

Dr French is a cell and molecular biologist who has been involved in the corporate biotechnology industry since 1998, when he founded stem cell storage company Cryosite Limited. From 2002 to 2006 he served as Managing Director of Probiomics Limited (a predecessor of Bioxyne) where he led the launch of six probiotic products based on the Company's *Lactobacillus fermentum* PCC strain in pharmacies in Australia and Singapore, as well as setting up a number of clinical studies on PCC.

Until December 2015, Dr French was the Managing Director of Benitec Biopharma Limited (ASX.BLT), Australia's only gene therapy company, which also successfully dual listed on the NASDAQ in late 2015.

Dr French holds a PhD in cell biology and an MBA from Deakin University. He was awarded a BSc, majoring in Microbiology, and an MSc in cancer research from the University of Sydney. In December

2015 he received an Australian Academy of Technology and Engineering award as an "Innovator of Influence, 2015" from the Chief Scientist of Australia, Professor Alan Finkel.

Tony Ho, Chairman of Bioxyne said, "We are excited to appoint Peter as our Executive Director to drive and grow our probiotics business. Peter is well known for his leadership in the life science and wellness sectors both in Australia and globally. Crucially, his background and experience in R&D and commercialisation of PCC means that he is eminently suited for the role."

For more information please contact:

Tony Ho Non-executive chairman Bioxyne Limited +61 417 345 839